Last checked at 23 Jul 2013 07:00

Â
Scancell Holdings Plc
("Scancell"or the "Company")
Â
Director Shareholdings
Â
Â
The Company has been informed that on 22 July 2013 certain Directors of the Company purchased ordinary shares in the Company as follows:
Â
Director | No. of Shares purchased  | Price at which shares purchased | No. of shares held pursuant to transaction (% of ISC following transaction) |
David Evans | 30,000 | 31.8 pence | 5,130,000 (2.6%) Â |
Kate Cornish-Bowden | 45,000 | 32.0 pence | 45,000 (0.02%) Â |
Â
Â
For Further Information:
Â
Scancell Holdings Plc Dr Richard Goodfellow, Joint CEO Professor Lindy Durrant, Joint CEO | + 44 (0) 74 2323 0 497  | |
Cenkos Securities: | +44 (0) 20 7397 8900 | |
Camilla Hume Stephen Keys | ||
FTI Consulting | +44 (0) 20 7831 3113 | |
Simon Conway Mo Noonan |
Â
Â
Â
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditopeâ„¢ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
Â
Â